Study S000447

A Phase 1, Open-label, Randomized, Parallel-group, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 133 Administered Subcutaneously in Chinese Subjects With Obesity or Overweight

ClinicalTrials.gov record

Registration

Registration: NCT06352892
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 20
Start: 2024-04-25
Primary completion: 2024-08-27
Lead sponsor: Amgen
Conditions: Obesity
Interventions: DRUG:Maridebart Cafraglutide
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Maximum Observed Plasma Concentration (Cmax) of Maridebart Cafraglutide [Up to approximately 120 days]
Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to the Last Quantifiable Concentration (AUClast) of Maridebart Cafraglutide [Up to approximately 120 days]
AUC from Time Zero Extrapolated to Infinity (AUCinf) of Maridebart Cafraglutide [Up to approximately 120 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.